Is bronchopulmonary dysplasia in adult age a novel COPD endotype?
- PMID: 36175025
- DOI: 10.1183/13993003.00984-2022
Is bronchopulmonary dysplasia in adult age a novel COPD endotype?
Conflict of interest statement
Conflict of interest: L. Bonadies has nothing to declare. A. Papi reports grants from Chiesi, AstraZeneca, GSK, BI, Pfizer, Teva and Sanofi; consulting fees from Chiesi, AstraZeneca, GSK, Novartis, Sanofi, Iqvia, Avillion and Elpen Pharmaceuticals; honoraria from Chiesi, AstraZeneca, GSK, BI, Menarini, Novartis, Zambon, Mundipharma, Teva, Sanofi, Edmond Pharma, Iqvia, MSD, Avillion and Elpen Pharmaceuticals; all of the above were not related to this specific work. E. Baraldi reports consulting fees from AstraZeneca, Sanofi and Exobiologics outside the submitted work.
Comment on
-
Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia.Eur Respir J. 2022 Sep 29;60(3):2102531. doi: 10.1183/13993003.02531-2021. Print 2022 Sep. Eur Respir J. 2022. PMID: 35210327 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical